The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Is The Forecasted Rise In Market Size Of The Primary Biliary Cholangitis Therapeutics Market During The Forecast Period?
The primary biliary cholangitis therapeutics market has experienced significant growth in recent years. Its value is projected to rise from $1.01 billion in 2025 to $1.14 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.9%. This historical growth can be ascribed to factors such as restricted treatment options for PBC, the rising prevalence of autoimmune liver diseases, enhanced liver disease awareness initiatives, the sustained reliance on ursodeoxycholic acid monotherapy, and the expansion of hospital infrastructure catering to liver disease care.
The primary biliary cholangitis therapeutics market size is anticipated to experience substantial growth over the next few years. It is projected to expand to $1.85 billion in 2030, driven by a compound annual growth rate (CAGR) of 12.9%. This expansion during the forecast period can be attributed to the ongoing development of obeticholic acid and combination therapies, an increase in investigational drugs and pipeline candidates, growing adoption of receptor agonists and modulators, enhanced patient awareness and early diagnosis initiatives, and the expansion of online and retail pharmacy distribution networks. Key trends for the forecast period include the rising acceptance of ursodeoxycholic acid and obeticholic acid treatments, an increase in combination therapies and pipeline drugs, a stronger focus on early diagnosis and disease monitoring, the broadening of hospital and retail pharmacy distribution channels, and greater awareness of autoimmune liver diseases and patient education.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25887&type=smp
What Core Drivers Are Transforming The Primary Biliary Cholangitis Therapeutics Market?
The primary biliary cholangitis therapeutics market is anticipated to experience growth driven by the rising incidence of liver diseases. Liver diseases encompass various conditions that compromise normal liver function, frequently resulting in inflammation, scarring, or liver failure. The increasing occurrence of these diseases is linked to higher alcohol consumption, as excessive intake damages liver cells, leading to inflammation and persistent liver conditions. Therapeutics for primary biliary cholangitis aid in managing liver diseases by targeting bile duct inflammation, slowing the progression of the disease, and preserving liver function. These treatments improve patient outcomes by alleviating symptoms, enhancing the quality of life, and delaying the necessity for liver transplantation. For instance, in September 2025, the Centers for Disease Control and Prevention (CDC), a US-based federal public health agency, reported that chronic liver disease and cirrhosis led to 52,222 deaths in the United States in 2023, establishing it as the ninth leading cause of death. Thus, the increasing prevalence of liver diseases is a significant impetus for the expansion of the primary biliary cholangitis therapeutics market.
How Is The Primary Biliary Cholangitis Therapeutics Market Structured Across Different Market Segments?
The primary biliary cholangitis therapeutics market covered in this report is segmented –
1) By Drug: Ursodeoxycholic Acid, Obeticholic Acid, Other Drugs
2) By Mechanism Of Action (MOA): Receptor Agonist, Receptor Modulator, Enzyme Activator, Enzyme Inhibitor, Other Mechanisms Of Action
3) By Distribution Channel: Hospital Pharmacies, Drug Store And Retail Pharmacies, Online Pharmacies
4) By Use: Human, Veterinary
Subsegments:
1) By Ursodeoxycholic Acid: Branded Ursodeoxycholic Acid, Generic Ursodeoxycholic Acid, Combination Therapies With Ursodeoxycholic Acid
2) By Obeticholic Acid: Monotherapy, Combination Therapy, Branded Obeticholic Acid
3) By Other Drugs: Fibrates, Budesonide, Immunosuppressants, Investigational Drugs Or Pipeline Candidates
What Trends Are Driving Changes In The Primary Biliary Cholangitis Therapeutics Market?
Leading companies within the primary biliary cholangitis therapeutics market are concentrating on developing advanced products and securing regulatory approvals, such as for peroxisome proliferator-activated receptor agonists, to enhance bile acid metabolism and decelerate disease progression in patients. These peroxisome proliferator-activated receptor (PPAR) agonists are medications designed to activate PPAR proteins, which are instrumental in regulating genes associated with metabolism, inflammation, and energy balance. For example, in August 2024, Gilead Sciences Inc., a US-based pharmaceutical company, obtained accelerated approval from the U.S. Food and Drug Administration (FDA) for Livdelzi (seladelpar). This approval targets the treatment of primary biliary cholangitis (PBC) in adults who have shown an insufficient response to ursodeoxycholic acid (UDCA) or cannot tolerate it. Livdelzi is an oral, selective PPARδ agonist that functions by stimulating the PPARδ receptor to regulate genes involved in reducing liver inflammation, optimizing bile acid metabolism, and slowing the progression of primary biliary cholangitis (PBC).
Which Organizations Are Operating Within The Primary Biliary Cholangitis Therapeutics Market?
Major companies operating in the primary biliary cholangitis therapeutics market are Novartis AG, Gilead Sciences Inc., Ipsen Pharma, Intercept Pharmaceuticals, Enanta Pharmaceuticals, Mirum Pharmaceuticals, Calliditas Therapeutics AB, Dr. Falk Pharma GmbH, NGM Biopharmaceuticals Inc., COUR Pharmaceuticals, HighTide Therapeutics Inc., Pliant Therapeutics Inc., Tiziana Life Sciences, Phenex Pharmaceuticals, Synlogic Therapeutics
Access The Complete Primary Biliary Cholangitis Therapeutics Market Report:
What Is The Largest Regional Market In The Primary Biliary Cholangitis Therapeutics Market?
North America was the largest region in the primary biliary cholangitis therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary biliary cholangitis therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Primary Biliary Cholangitis Therapeutics Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=25887&type=smp
Browse Through More Reports Similar to the Global Primary Biliary Cholangitis Therapeutics Market 2026, By The Business Research Company
Primary Biliary Cholangitis Market Report 2026
https://www.thebusinessresearchcompany.com/report/primary-biliary-cholangitis-global-market-report
Liver Diseases Therapeutics Market Report 2026
https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report
Cholinergic Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/cholinergic-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model